We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Researchers Developing 'Lab-in-Box' Kit for Medium Throughput Processing of COVID-19 Samples for Detection Using RT-PCR

By LabMedica International staff writers
Posted on 10 Nov 2020
A team of scientists is developing viral RNA extraction kits for medium-throughput processing of COVID-19 samples for detection using RT-PCR. More...


Magnostics Ltd. (Dublin, Ireland) is leading a consortium of scientists to develop and launch viral RNA extraction kits for the detection of COVID-19. To detect the SARS-CoV-2 virus, which causes COVID-19 infection, a very small number of RNA viral genomes must be isolated from the nasal swab. This is a stereotypical needle in the haystack problem where there are a very small number of viruses among tens of thousands of much larger cells. The team of scientists has developed necessary protocols for SARS-cov-2 testing based on Magnostics' Si@Hi-Mag superparamagnetic beads. The key is to use Si@Hi-mag magnetic nanoparticles to capture the RNA from the complicated soup that makes up the virus lysate, which includes proteins, lipids, and other cellular components, and then use a powerful magnet to move and thus separate the magnetic nanoparticles. This allows a series of solutions to be used to rinse the RNA-nanoparticle complex and then release the RNA into a buffer that can be used for reverse transcription and quantitative detection with the polymerase chain reaction (PCR).

Using test samples from patients, the team has proven that Si@Hi-mag beads can be used to extract viral RNA from clinical samples. This includes Lysis buffer, which inactivates and bursts open the virus, superparamagnetic nanoparticles, and a rare-earth magnet array for medium-throughput processing. This important demonstration forms the basis for Magnostics to develop a CE marked 'lab-in-box' kit for the medium throughput manual extraction of viral RNA from clinical samples. The product will allow clinical laboratories to perform 400-600 extractions per day using existing infrastructure.

Related Links:
Magnostics Ltd.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.